Detalhe da pesquisa
1.
Safety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study.
Int J Gynecol Cancer
; 33(4): 562-570, 2023 04 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36564099
2.
Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial.
Lancet Oncol
; 23(4): 540-552, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35358455
3.
Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial.
Lancet Oncol
; 22(5): 678-689, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33848462
4.
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials.
Lancet Oncol
; 21(4): 531-540, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32105622
5.
Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study.
Am J Hematol
; 95(4): 362-371, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31868245
6.
PI3K inhibitors in haematological malignancies.
Lancet Oncol
; 23(8): e365, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35901826
7.
A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube.
Gynecol Oncol
; 132(3): 517-25, 2014 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24476788
8.
Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial.
Lancet Oncol
; 14(1): 72-80, 2013 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-23246022
9.
Model-Based Benefit/Risk Analysis for the Copanlisib Intermittent Dosing Regimen.
Clin Pharmacol Ther
; 115(5): 1092-1104, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38226495
10.
Addition of bevacizumab to three docetaxel regimens as adjuvant therapy for early stage breast cancer.
Breast Cancer Res Treat
; 142(3): 655-65, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24253810
11.
Model-informed approach to support pediatric dosing for the pan-PI3K inhibitor copanlisib in children and adolescents with relapsed/refractory solid tumors.
Clin Transl Sci
; 16(7): 1197-1209, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37042099
12.
Copanlisib population pharmacokinetics from phase I-III studies and exposure-response relationships in combination with rituximab.
CPT Pharmacometrics Syst Pharmacol
; 12(11): 1666-1686, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37389853
13.
Safety and antitumor activity of copanlisib in Japanese patients with relapsed/refractory indolent non-Hodgkin lymphoma: a phase Ib/II study.
Int J Hematol
; 117(1): 100-109, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36175779
14.
A phase I pharmacokinetic study of copanlisib in Chinese patients with relapsed indolent non-Hodgkin lymphoma.
Cancer Chemother Pharmacol
; 89(6): 825-831, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35322287
15.
Triple negative breast cancer: unmet medical needs.
Breast Cancer Res Treat
; 125(3): 627-36, 2011 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-21161370
16.
Feasibility of Combining the Phosphatidylinositol 3-Kinase Inhibitor Copanlisib With Rituximab-Based Immunochemotherapy in Patients With Relapsed Indolent B-cell Lymphoma.
Clin Lymphoma Myeloma Leuk
; 21(11): e886-e894, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34389273
17.
Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphoma.
Blood Adv
; 5(3): 823-828, 2021 02 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33560394
18.
Quality of Life in Adult and Pediatric Patients with Tropomyosin Receptor Kinase Fusion Cancer Receiving Larotrectinib.
Curr Probl Cancer
; 45(6): 100734, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33865615
19.
Emergence of nonanthracycline regimens in the adjuvant treatment of breast cancer.
Breast Cancer Res Treat
; 119(1): 25-32, 2010 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-19795206
20.
Larotrectinib versus Prior Therapies in Tropomyosin Receptor Kinase Fusion Cancer: An Intra-Patient Comparative Analysis.
Cancers (Basel)
; 12(11)2020 Nov 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33158040